Testosterone treatment for pain relief in men with opioid-induced low testosterone
Official title: Androgen Replacement to Improve Patient-Important Outcomes in Men With Opioid-Induced Hypogonadism
Run by Brigham and Women's Hospital · NCT04798469 · Data updated 2026-11-12
This study is testing if testosterone treatment can help men with chronic spinal pain and low testosterone from using opioids feel better and improve their quality of life.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 150 (estimated) |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | January 10, 2022 |
| Main results expected | September 30, 2027 |
| Study ends | December 30, 2027 |
| Registry record updated | July 27, 2026 |
| Trial ID | NCT04798469 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men aged 18 years and older with chronic non-cancer spinal pain who have been on opioid analgesics for at least six months and have low testosterone levels.
✕Probably not a fit
Patients with a history of prostate cancer, organic hypogonadism, or other specified medical conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to assess the effectiveness of testosterone replacement therapy in improving pain perception, pain tolerance, sexual function, fatigue, and quality of life in men suffering from chronic spinal pain and opioid-induced hypogonadism. The study is designed as a single-center, randomized, double-blind, placebo-controlled trial, where participants will receive either testosterone undecanoate or a placebo for six months. Eligible participants are men aged 18 and older who have been using opioid analgesics for at least six months and have low testosterone levels. The outcomes will be compared between the testosterone and placebo groups to determine the therapy's efficacy.
Why it matters
Potential benefit: If successful, this treatment could significantly improve pain management and overall quality of life for men with opioid-induced hypogonadism.
How similar studies have gone: Other studies have explored testosterone therapy in similar contexts, but this specific approach in opioid-induced hypogonadism is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men, age 18 years and older. * Chronic non-cancer spinal pain. * Use of opioid analgesics for at least 6 months. * Serum total testosterone (measured by mass spectrometry) \<348 ng/dL and/or free testosterone \<70 pg/mL. * Ability and willingness to provide informed consent. Exclusion Criteria: * History of prostate cancer or breast cancer. * Known history of organic hypogonadism (e.g., due to hypothalamic, pituitary or testicular disease). * Use of testosterone within the past 6 months. * Baseline hematocrit \>48%. * Prostate-specific antigen (PSA) level \>4 ng/mL in Caucasians or \>3 ng/mL in African-Americans. * Presence of prostate nodule or induration on digital rectal examination. * Uncontrolled congestive heart failure. * Myocardial infarction, acute coronary syndrome, revascularization surgery or stroke within 3 months. * Serum creatinine \>2.5 mg/dL. * Alanine aminotransferase (ALT) level 3 times above the upper limit of normal. * Diagnosis of bipolar disorder or schizophrenia. * Presence of metallic implants (pacemakers, aneurysm clips, etc.) that preclude the patient from undergoing functional magnetic resonance imaging (MRI). In subjects who are otherwise eligible and either do not qualify for MRI or are reluctant to undergo imaging, the investigators may consider enrolling such participants on a case-by-case basis.
Where it's running
-
Brigham and Women's Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Shehzad Basaria, MD — Brigham and Women's Hospital
- Study coordinator: Julia Crosby
- Email: jpcrosby@bwh.harvard.edu
- Phone: 617-525-6726
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Exercise Self-Efficacy, Body Composition, and Activity in Men with Low Testosterone
This study tests how confident men on testosterone therapy are at staying active and whether that confidence links body fat and lean mass with how much they exercise.
-
Male Hypogonadism: How Stigma and Identity relate to Quality of Life
This study tests whether men with hypogonadism feel more anticipated stigma and have a different illness identity compared with men with other chronic endocrine conditions, and whether those psychosocial factors predict quality of life.
-
Serratus vs Erector Spinae Block for Pain After Unilateral Breast Surgery
This trial tests whether serratus posterior superior intercostal plane block or erector spinae plane block reduces chronic pain 3 months after unilateral breast surgery in adult women.
-
Using mHealth to Help Black Adults in the Midwest With Opioid/Stimulant Use and Mood Symptoms
This study tests a mobile health program to support recovery and mood in Black adults who use opioids or stimulants and are seeking treatment.
-
Targeting alcohol-opioid co-use among young adults with a new mobile health tool
A mobile health app is being tested to help young adults reduce drinking and opioid use when they occur together.
-
Dexa vs Dexmedetomidine with Bupivacaine in TAP Block for Laparotomy Analgesia
This study tests whether adding dexamethasone or dexmedetomidine to bupivacaine in a TAP block improves postoperative pain control after laparotomy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.